Genetics: Human genome editing in heart disease (Nature Clinical Practice Cardiovascular Medicine)

Human germline genome editing with CRISPR–Cas9 can be used with high efficiency, accuracy, and safety to correct a heterozygous, autosomal dominant mutation in MYBPC3 associated with hypertrophic cardiomyopathy, according to a new study in Nature.CRISPR–Cas9 is a versatile tool for recognizing a